8492359

Arbutus and Genevant sued Moderna over the Moderna COVID-19 vaccine, originally asserting six patents including US 8,822,668. The '668 patent was dropped during bilateral narrowing before trial. The case settled globally on March 3, 2026, with Moderna consenting to judgment on the four surviving patents, and Moderna later appealed.

Moderna's appeal from the District of Delaware action, primarily raising its 28 U.S.C. § 1498 government-contractor immunity defense. US 8,822,668 is tagged to the appeal via the underlying docket, but the appeal concerns the four patents actually adjudicated.

Arbutus and Genevant sued Moderna and ModernaTX in D. Del. asserting six LNP patents, including 11141378. The case settled March 3, 2026 as part of a $2.25 billion global settlement; Moderna consented to a judgment of infringement and no invalidity on four asserted patents, and the docket terminated March 4, 2026.

Arbutus and Genevant sued Pfizer and BioNTech in D.N.J. over Comirnaty, asserting 11141378 plus 9504651, 8492359, 11298320, and 11318098. The case remains pending with claim construction on September 9, 2025, and ongoing discovery as of April 26, 2026.

Reported but unconfirmed D.N.J. declaratory-judgment action by Acuitas against Arbutus and Genevant, challenging a list of patents including 11141378 and other Arbutus family patents. The narrative could not independently verify the case number 3:23-cv-04200 against the Acuitas caption.

Arbutus and Genevant asserted five LNP patents, including the '359 patent, against Pfizer and BioNTech over Comirnaty. The action remains pending after a September 2025 claim construction ruling and was carved out of the Moderna settlement.

Acuitas refiled its declaratory-judgment action against Genevant and Arbutus in D.N.J. on August 4, 2023, again seeking declarations that Comirnaty does not infringe and that ten Arbutus patents are invalid. The narrative could not verify the D.N.J. case number; a possible 3:23-cv-04200 identification was expressly treated as unverified.